Reply to Z Wen et al and S Liu et al

Hatem A Azim¹, Samuel M Niman¹, Ann H Partridge¹+5

• ¹Hatem A. Azim Jr, MD, PhD, Cairo Cure Oncology Center, Cairo, Egypt; Samuel M. Niman, MSc, International Breast Cancer Study Group Statistical Center, Boston, MA, Division of Biostatistics, Department of Data Science, Dana-Farber Cancer Institute, Boston, MA; Ann H. Partridge, MD, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, Harvard Medical School, Boston, MA; Isabelle Demeestere, MD, PhD, Research Laboratory on Human Reproduction, Université Libre de Bruxelles (ULB), Brussels, Belgium, Gynecology and Obstetrics Department, Fertility Clinic, HUB-Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium; Monica Ruggeri, MM, Program for Young Patients, International Breast Cancer Study Group, A Division of ETOP IBCSG Partners Foundation, Bern, Switzerland; Richard D. Gelber, PhD, International Breast Cancer Study Group Statistical Center, Boston, MA, Division of Biostatistics, Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, Frontier Science Foundation, Boston, MA, Harvard TH Chan School of Public Health, Boston, MA; Olivia Pagani, MD, Geneva University Hospitals, Geneva, Switzerland; Lugano University, Lugano, Switzerland, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; and Fedro A. Peccatori, MD, PhD, Fertility and Procreation Unit, Gynecologic Oncology Program, IEO, European Institute of Oncology IRCCS, Milan, Italy.